|1||Active, not recruiting||
Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)
|2||Active, not recruiting||
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
† Study has passed its completion date and status has not been verified in more than two years.